Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

More articles from 1-Minute consult

  • Who should receive hepatitis A vaccine?
    You have access
    Who should receive hepatitis A vaccine?
    Steven D. Mawhorter, MD
    Cleveland Clinic Journal of Medicine October 2001, 68 (10) 825-827;

    Vaccination is recommended for overseas travelers, children, older adults, transplant recipients, patients with chronic liver disease, and others at risk.

  • You have access
    At what level of hyperkalemia or creatinine elevation should ACE inhibitor therapy be stopped or not started?
    Saul Nurko, MD
    Cleveland Clinic Journal of Medicine September 2001, 68 (9) 754-760;

    These drugs are a double-edged sword: they slow the decline in renal function in many patients, yet reduce renal function in some.

  • Should amphetamines be added to SSRI therapy to enhance the antidepressant effect?
    You have access
    Should amphetamines be added to SSRI therapy to enhance the antidepressant effect?
    Vivek Singh, MD and Donald A. Malone, MD
    Cleveland Clinic Journal of Medicine September 2001, 68 (9) 748-749;

    Despite anecdotal reports of an additive effect, no firm conclusions can be drawn.

  • You have access
    Should we still be using theophylline to treat asthma?
    Marta M. Vielhaber, MD and Mani Kavuru, MD
    Cleveland Clinic Journal of Medicine August 2001, 68 (8) 681;

    With better drugs available, theophylline has been relegated to fourth-line status.

  • Should the actual or the corrected serum sodium be used to calculate the anion gap in diabetic ketoacidosis?
    You have access
    Should the actual or the corrected serum sodium be used to calculate the anion gap in diabetic ketoacidosis?
    Laurence H. Beck, MD
    Cleveland Clinic Journal of Medicine August 2001, 68 (8) 673-674;

    The two values have different uses: use the measured value to calculate the anion gap and the corrected value to assess dehydration.

  • How should hyperuricemia be treated in a patient with allopurinol hypersensitivity?
    You have access
    How should hyperuricemia be treated in a patient with allopurinol hypersensitivity?
    Stefan D. Monev, MD
    Cleveland Clinic Journal of Medicine July 2001, 68 (7) 597-598;

    If other methods of lowering uric acid fail, desensitization to allopurinol is an option but poses serious risks.

  • You have access
    Does salmeterol increase mortality in patients with COPD?
    Robert B. Gerber, MD and Mani Kavuru, MD
    Cleveland Clinic Journal of Medicine July 2001, 68 (7) 600-601;

    Salmeterol is safe and FDA-approved, but it should be used only as part of a total program that includes education, smoking cessation, oxygen supplementation, and rehabilitation.

  • You have access
    Is glucosamine an effective treatment for osteoarthritic pain?
    Michele Hooper, MD
    Cleveland Clinic Journal of Medicine June 2001, 68 (6) 494-495;

    Glucosamine shows promise, but studies had flaws that render much of the data inconclusive.

  • When should digoxin be used in patients with diastolic dysfunction?
    You have access
    When should digoxin be used in patients with diastolic dysfunction?
    M. Hilal Yamani, MD
    Cleveland Clinic Journal of Medicine June 2001, 68 (6) 481;

    Treatment with digoxin must be individualized.

  • You have access
    Should patients with severe heart failure be treated with beta-blockers?
    Robert E. Hobbs, MD
    Cleveland Clinic Journal of Medicine May 2001, 68 (5) 469-470;

    A recent major trial showed that a beta-blocker can indeed be beneficial in severe heart failure, if used cautiously.

Pages

  • Previous
  • Next
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire